1
|
Lei Y, Yang Y, Yang G, Li A, Yang Y, Wang Y, Gao C. Delivery Strategies for Colchicine as a Critical Dose Drug: Reducing Toxicity and Enhancing Efficacy. Pharmaceutics 2024; 16:222. [PMID: 38399276 PMCID: PMC10891573 DOI: 10.3390/pharmaceutics16020222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2024] [Revised: 01/29/2024] [Accepted: 01/29/2024] [Indexed: 02/25/2024] Open
Abstract
Colchicine (COL), a widely used natural drug, has potent anti-inflammatory effects; however, as a narrow therapeutic index drug, its clinical application is limited by its serious gastrointestinal adverse effects, and only oral formulations are currently marketed worldwide. Recent studies have shown that transdermal, injection, and oral drug delivery are the three main delivery strategies for COL. This article elaborates on the research progress of different delivery strategies in terms of toxicity reduction and efficacy enhancement, depicting that the transdermal drug delivery route can avoid the first-pass effect and the traumatic pain associated with the oral and injection routes, respectively. Therefore, such a dosage form holds a significant promise that requires the development of further research to investigate effective COL delivery formulations. In addition, the permeation-promoting technologies utilized for transdermal drug delivery systems are briefly discussed. This article is expected to provide scientific ideas and theoretical guidance for future research and the exploration of COL delivery strategies.
Collapse
Affiliation(s)
- Yaran Lei
- State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China; (Y.L.); (Y.Y.); (G.Y.); (A.L.); (Y.Y.)
- School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Benxi 117004, China
| | - Yulu Yang
- State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China; (Y.L.); (Y.Y.); (G.Y.); (A.L.); (Y.Y.)
- School of Pharmacy, Guangxi Medical University, Nanning 530021, China
| | - Guobao Yang
- State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China; (Y.L.); (Y.Y.); (G.Y.); (A.L.); (Y.Y.)
| | - Ao Li
- State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China; (Y.L.); (Y.Y.); (G.Y.); (A.L.); (Y.Y.)
- School of Pharmacy, Henan University, Kaifeng 475004, China
| | - Yang Yang
- State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China; (Y.L.); (Y.Y.); (G.Y.); (A.L.); (Y.Y.)
| | - Yuli Wang
- State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China; (Y.L.); (Y.Y.); (G.Y.); (A.L.); (Y.Y.)
| | - Chunsheng Gao
- State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China; (Y.L.); (Y.Y.); (G.Y.); (A.L.); (Y.Y.)
| |
Collapse
|
2
|
Anjani QK, Sabri AHB, Moreno-Castellanos N, Utomo E, Cárcamo-Martínez Á, Domínguez-Robles J, Wardoyo LAH, Donnelly RF. Soluplus®-based dissolving microarray patches loaded with colchicine: towards a minimally invasive treatment and management of gout. Biomater Sci 2022; 10:5838-5855. [PMID: 35972236 DOI: 10.1039/d2bm01068b] [Citation(s) in RCA: 18] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Considered as one of the most common inflammatory arthritis, gout is characterised by a sudden onset of severe joint pain. As the first-line drug of choice used in treating acute gout, colchicine (CLC) is hindered by poor gastrointestinal permeability as well as unfavourable gastrointestinal side effects. Herein, we present, for the first time, the preparation of microarray array patches (MAPs) made of a polymeric solubiliser, Soluplus®, loaded with CLC for its systemic delivery. The fabricated MAPs displayed acceptable mechanical properties and were capable of being inserted into the skin to a depth of ≈500 μm in full thickness ex vivo neonatal porcine skin, as evidenced by optical coherence tomography. In vitro dermatokinetic studies utilising full thickness neonatal porcine skin demonstrated that the CLC-loaded MAPs delivered CLC across all skin strata, resulting in a delivery efficiency of 73% after 24 hours. Furthermore, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) and cell proliferation assays along with LIVE/DEAD™ staining on the 3T3-L1 cell line showed that the MAP formulation displayed minimal toxicity, with acceptable biocompatibility. Lastly, the anti-inflammatory properties of the formulation were evaluated using a THP-1 macrophage cell line. It was shown that treatment of THP-1 macrophages that are exposed to lipopolysaccharide (LPS) with CLC-loaded MAPs caused a significant (p < 0.05) reduction of TNF-α production, a pro-inflammatory cytokine typically associated with the early onset of acute gout. Accordingly, CLC-loaded MAPs could represent a new minimally-invasive alternative strategy for management of acute gout.
Collapse
Affiliation(s)
- Qonita Kurnia Anjani
- School of Pharmacy, Queen's University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast BT9 7BL, UK. .,Fakultas Farmasi, Universitas Megarezky, Jl. Antang Raya No. 43, Makassar 90234, Indonesia
| | - Akmal Hidayat Bin Sabri
- School of Pharmacy, Queen's University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast BT9 7BL, UK.
| | - Natalia Moreno-Castellanos
- Basic Science Department, Faculty of Health, Universidad Industrial de Santander, Bucaramanga 680001, Colombia
| | - Emilia Utomo
- School of Pharmacy, Queen's University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast BT9 7BL, UK.
| | - Álvaro Cárcamo-Martínez
- School of Pharmacy, Queen's University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast BT9 7BL, UK.
| | - Juan Domínguez-Robles
- School of Pharmacy, Queen's University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast BT9 7BL, UK.
| | - Luki Ahmadi Hari Wardoyo
- Fakultas Seni Rupa dan Desain, Institut Teknologi Bandung, Jl. Ganesa No.10, Bandung 40132, Indonesia
| | - Ryan F Donnelly
- School of Pharmacy, Queen's University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast BT9 7BL, UK.
| |
Collapse
|
3
|
Aboumanei MH, Mahmoud AF. Development of Tamoxifen In Situ Gel Nanoemulsion for Ocular Delivery in Photoreceptor Degeneration Disorder: In Vitro Characterization, 131I-Radiolabeling, and In Vivo Biodistribution Studies. J Pharm Innov 2022. [DOI: 10.1007/s12247-022-09638-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Abstract
Purpose
The aim of our work is to develop an in situ ocular gellan gum–based nanoemulsion (NE) of tamoxifen TAM as an alternative drug delivery system to the oral route for the treatment of photoreceptor degeneration disorder.
Method
Six pseudoternary phase diagrams were developed using oil (oleic acid), surfactants (Tween 80 or Tween 20), a co-surfactant (polyethylene glycol 400), and water. The particle size, polydispersity index, and zeta potential of the developed systems were all measured. The safety of ocular application of the optimum system was established via in vivo histopathological investigation. To track the biodistribution of the optimum gel, iodine-131 (131I) was incorporated into the gel via coupling with TAM via direct electrophilic substitution reaction.
Results
Based on the obtained results, TAMNE-1 was chosen as the optimal system, with PS = 140.20 ± 1.50 nm, ZP = − 27.86 ± 1.13 mV, and PDI = 0.20 ± 0.00%. In vitro release displayed a prolonged and sustained release of TAMNE-1 gel compared to TAM solution (plain eye drop). Transparent in situ TAMNE-1 gel was developed after the incorporation of the TAMNE-1 system into gellan gum aqueous solution (0.3% w/w). In this study, TAM was successfully radiolabeled with 131I for subsequent evaluation of the efficacy of the developed in situ gel system (TAMNE-1 gel) in vivo. The developed TAMNE-1 gel system was nonirritant and safe and the biodistribution studies showed better retention of TAMNE-1 gel than plain TAM eye drops.
Conclusion
The developed TAMNE-1 gel is able to enhance the ocular bioavailability of TAM and can go further with clinical evaluation.
Graphic Abstract
Collapse
|